O. Saunders

442 total citations
15 papers, 366 citations indexed

About

O. Saunders is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, O. Saunders has authored 15 papers receiving a total of 366 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in O. Saunders's work include Cancer Treatment and Pharmacology (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). O. Saunders is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). O. Saunders collaborates with scholars based in United Kingdom, United States and Netherlands. O. Saunders's co-authors include Jane Robertson, Thomas A. Puchalski, Juliane M. Jürgensmeier, Ute Zirrgiebel, Joachim Drevs, Clemens Unger, Helen Young, Jan Harder, Ralph Strecker and K. Mross and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Respiratory Journal.

In The Last Decade

O. Saunders

15 papers receiving 356 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
O. Saunders United Kingdom 7 197 188 156 69 50 15 366
Tuan S. Nguyen United States 10 133 0.7× 150 0.8× 80 0.5× 35 0.5× 32 0.6× 19 338
Davide Bosso Italy 12 133 0.7× 132 0.7× 167 1.1× 70 1.0× 29 0.6× 18 366
K. Hoekman Netherlands 6 166 0.8× 128 0.7× 60 0.4× 72 1.0× 22 0.4× 11 323
Ioannis Xanthakis Greece 12 125 0.6× 347 1.8× 161 1.0× 93 1.3× 57 1.1× 30 519
Dénes Csonka Switzerland 5 231 1.2× 148 0.8× 191 1.2× 70 1.0× 80 1.6× 14 464
Silvana Vignati Italy 7 257 1.3× 184 1.0× 218 1.4× 152 2.2× 53 1.1× 9 489
Valentina Tateo Italy 10 114 0.6× 205 1.1× 150 1.0× 96 1.4× 18 0.4× 36 437
Karen Giselle Chee United States 7 102 0.5× 182 1.0× 163 1.0× 36 0.5× 49 1.0× 9 380
Eric D. Mininberg United States 3 192 1.0× 345 1.8× 307 2.0× 96 1.4× 37 0.7× 6 494
Jitka Abrahámová Czechia 10 168 0.9× 147 0.8× 182 1.2× 91 1.3× 12 0.2× 44 406

Countries citing papers authored by O. Saunders

Since Specialization
Citations

This map shows the geographic impact of O. Saunders's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O. Saunders with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O. Saunders more than expected).

Fields of papers citing papers by O. Saunders

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O. Saunders. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O. Saunders. The network helps show where O. Saunders may publish in the future.

Co-authorship network of co-authors of O. Saunders

This figure shows the co-authorship network connecting the top 25 collaborators of O. Saunders. A scholar is included among the top collaborators of O. Saunders based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O. Saunders. O. Saunders is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Ramaekers, Bram, et al.. (2020). R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study. PharmacoEconomics. 38(7). 765–776. 8 indexed citations
2.
3.
4.
McCarthy, Philip L., Paul G. Richardson, Vera J. Suman, et al.. (2018). Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance 100104). Blood. 132(Supplement 1). 4737–4737. 2 indexed citations
5.
6.
7.
8.
Roskell, Neil, O. Saunders, Dawn Lee, & Mark Fisher. (2014). Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis. European Respiratory Journal. 44(Suppl 58). 1905–1905. 4 indexed citations
9.
Cruijsen, Hester van, Emile E. Voest, Cornelis J.A. Punt, et al.. (2010). Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. European Journal of Cancer. 46(5). 901–911. 47 indexed citations
10.
Scheulen, M. E., K. Mross, Heike Richly, et al.. (2010). A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). e13065–e13065. 6 indexed citations
11.
Scheulen, M. E., K. Mross, Heike Richly, et al.. (2010). 496 A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumours. European Journal of Cancer Supplements. 8(7). 158–159. 1 indexed citations
12.
Cunningham, David, G D’Haens, Jean‐Yves Douillard, et al.. (2008). A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS results. Journal of Clinical Oncology. 26(15_suppl). 4028–4028. 26 indexed citations
13.
Cruijsen, Hester van, Carla M.L. van Herpen, Klaas Hoekman, et al.. (2007). 705 POSTER Evaluation of thyroid function in an open-label Phase I study of AZD2171 with gefitinib. European Journal of Cancer Supplements. 5(4). 108–109. 1 indexed citations
14.
Herpen, C. van, Joachim Drevs, Hester van Cruijsen, et al.. (2007). Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): Combined results from two phase I studies. Journal of Clinical Oncology. 25(18_suppl). 3560–3560. 10 indexed citations
15.
Drevs, Joachim, Michael Medinger, K. Mross, et al.. (2007). Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 25(21). 3045–3054. 247 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tuan S. Nguyen Breakdown of academic impact, for papers by Davide Bosso Breakdown of academic impact, for papers by K. Hoekman Breakdown of academic impact, for papers by Ioannis Xanthakis Breakdown of academic impact, for papers by Dénes Csonka Breakdown of academic impact, for papers by Silvana Vignati Breakdown of academic impact, for papers by Valentina Tateo Breakdown of academic impact, for papers by Karen Giselle Chee Breakdown of academic impact, for papers by Eric D. Mininberg Breakdown of academic impact, for papers by Jitka Abrahámová
Rankless by CCL
2026